A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p16, on the other hand, acts through the Retinoblastoma (Rb) pathway (Serrano et al, 1993).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Serrano et al, 1993
In the citing paper
“p16INK4A is a 16 KDa protein that directly binds to CDK4/6 and blocks the formation of cyclinD-CDK4/6 complexes, thereby preventing phosphorylation of RB and promoting expression of E2F target genes (Serrano et al., 1993).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Serrano et al., 1993
In the citing paper
“This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [78]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Self-citationSherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Self-citationFunctional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Research works printed but not linked: 2
- Motokura, T. & Arnold, A. Biochim. biophys. Acta 1155, 63–78 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene (in the press).
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
“[937, 938] and ARF (an activator of p53) [939, 940]; (3)”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
“Oncogenic ras also induces proliferative arrest and differentiation inported that cells lacking functional Rb overexpress p16 (Serrano et al., 1993; Hara et al., 1996).”
BackgroundSelf-citationThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
“Similarly, the p16INK4A protein product of the CDKN2A tumour suppressor gene directly inhibits the kinases encoded by the oncogenes CDK4 and CDK6 (Ref”
BackgroundCellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“EGFRvIII is a highly validated glioma target as evidenced by the capacity of activated EGFR mutants to enhance tumorigenic behavior of human GBM cells by reducing apoptosis and increasing proliferation (Nishikawa et al. 1994; Nagane et al. 1996; Huang et al. 1997; Narita et al. 2002) and to malignantly transform murin…”
BackgroundCYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D., & Knippers, R. (2001) · PubMed · Cited by 2,549
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60702-2 · Cited by 1,928
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
“Soon after the discovery of p16INK4a (Serrano et al., 1993), and in the context of the search for factors that could explain cellular senescence, it was observed that p16INK4a levels accumulated progressively with Figure 3.”
Self-citationThe p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
“IGFBP3, IGFBP4, and IGFBP7 are key players of SASP that are suggested to be involved in mediating senescence by paracrine signaling (Wajapeyee et al., 2008; Severino et al., 2013; Özcan et al., 2016).”
BackgroundThe functional role of long non-coding RNA in human carcinomas
Gibb, E. A., Brown, C. J., & Lam, W. L. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-38 · Cited by 1,619
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Self-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Papillomavirus infections — a major cause of human cancers
Hausen, H. Z. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00020-0 · Cited by 1,513
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
“and James M. Roberts* inhibitors of the cyclin D‐CDK4/CDK6 kinases (Xiong et *Department of Basic Sciences al., 1993b; Serrano et al., 1993 ) and the Kip/Cip inhibitors.”
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
“The tumour suppressor protein p16 INK4a functions by binding to the cyclin-D-dependent protein kinases Cdk4 and 6, blocking their activity and preventing Rb phosphorylatio”
BackgroundSenescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Toxic effects of ultraviolet radiation on the skin
Matsumura, Y., & Ananthaswamy, H. N. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.08.019 · Cited by 1,270
“p16 is a CDK inhibitor that specifically inhibits progression through the G1 phase of the cell cycle in cells that express pRb (Serrano et al., 1993).”
BackgroundGermline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
“The product of the INK4a gene, p16, acts as an inhibitor of cyclin D-dependent kinases, preventing them from phosphorylating the retinoblastoma (pRb) protein and thus inhibiting S-phase entry during the cell division cycle (Serrano et al. 1993).”
BackgroundDi Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,408
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
“Apart from interacting with D-type cyclins, CDK4 and CDK6 can independently associate with INK4 proteins (Serrano et al., 1993; Guan et al., 1994; Hannon and Beach, 1994; Chan et al., 1995; Hirai et al., 1995).”
BackgroundA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Self-citationCorrelation of Terminal Cell Cycle Arrest of Skeletal Muscle with Induction of p21 by MyoD
Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., & Lassar, A. B. (1995) · Science · doi:10.1126/science.7863327 · Cited by 1,149
Self-citationHuman Cyclin E, a Nuclear Protein Essential for the G1-to-S Phase Transition
Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., & Pagano, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2612 · Cited by 1,148
“Similarly, overexpression of p16 or p18, two specific inhibitors of cyclin D-Cdk4 complexes (30, 80), prevents cell cycle progression only in pRb(1) cells (30, 16a, 45a, 51a, 79).”
BackgroundTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,136
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.
Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., & Jacks, T. (1995) · Genes & Development · doi:10.1101/gad.9.8.935 · Cited by 1,119
“Other cyclin/cdk inhibitors have since been identified and cloned (Serrano et al. 1993; Hannon and Black 1994; Polyak et al. 1994), including p16 (Serrano et al.”
BackgroundSelf-citationForging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
“1994); conversely, attenuation of Cdk4 activity by polypeptide inhibitors of the INK4 gene family (Serrano et al. 1993) or by Cdk4-selective drugs (Tetsu and McCormick 2003) results in G1-phase arrest and cell cycle exit.”
BackgroundLundberg, A. S., & Weinberg, R. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.753 · Cited by 1,067
“The cdk inhibitor p16 has previously been shown to inhibit cdk4/6 activity (52), and a dominantnegative form of cdk2, termed cdk2DN, has been shown to inhibit cdk2 activity (58).”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
“p16 inhibits cell cycle progression by inhibiting cyclin D-dependent kinases and thereby prevents the phosphorylation of the tumor suppressor Rb (Serrano et al. 1993), whereas p19arf prevents the degradation and inactivation of the tumor suppressor p53 by binding to Mdm2 (Pomerantz et al.”
Klaes, R., Friedrich, T., Spitkovsky, D., Ridder, R., Rudy, W., Petry, U., Dallenbach-Hellweg, G., Schmidt, D., & von Knebel Doeberitz, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1174 · Cited by 1,035
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
p53-Independent Expression of p21 Cip1 in Muscle and Other Terminally Differentiating Cells
Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., & Elledge, S. J. (1995) · Science · doi:10.1126/science.7863329 · Cited by 1,032
Inhibition of cyclin-dependent kinases by p21.
Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., & Swindell, E. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.4.387 · Cited by 1,023
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008
Self-citationThe INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
The common biology of cancer and ageing
Finkel, T., Serrano, M., & Blasco, M. A. (2007) · Nature · doi:10.1038/nature05985 · Cited by 988
Self-citationSherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Kapust, R. B., & Waugh, D. S. (1999) · Protein Science · doi:10.1110/ps.8.8.1668 · Cited by 960
“; MMP, matrix metalloproteinase; p16, human cyclin-dependent kinase 4 ~Cdk4! inhibitor ~Serrano et al., 1993!”
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
“The first recognized product of this locus was p16 Ink4a , an inhibitor of cyclin-D-dependent kinases that governs the ability of the retinoblastoma protein to control exit from the G1 phase of the cell cycle”
BackgroundMatsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., & Elledge, S. J. (1995) · Genes & Development · doi:10.1101/gad.9.6.650 · Cited by 952
Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., & Wang, X. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5545 · Cited by 950
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Self-citationCyclin‐dependent protein kinases: Key regulators of the eukaryotic cell cycle
Nigg, E. A. (1995) · BioEssays · doi:10.1002/bies.950170603 · Cited by 932
Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 911
The ankyrin repeat as molecular architecture for protein recognition
Mosavi, L. K., Cammett, T. J., Desrosiers, D. C., & Peng, Z. (2004) · Protein Science · doi:10.1110/ps.03554604 · Cited by 907
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889
Lee, M. H., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889
Liu, M., Lee, M. H., Cohen, M., Bommakanti, M., & Freedman, L. P. (1996) · Genes & Development · doi:10.1101/gad.10.2.142 · Cited by 890
Stein, G. H., Drullinger, L. F., Soulard, A., & Dulić, V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2109 · Cited by 868
“In contrast to p21 and p27, which bind to cyclin D-Cdk complexes, p16 binds exclusively to Cdk4/6, thus preventing their association with cyclin D (47, 50).”
BackgroundAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Translational Control of p27 Kip1 Accumulation During the Cell Cycle
Hengst, L., & Reed, S. I. (1996) · Science · doi:10.1126/science.271.5257.1861 · Cited by 846
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
“To further characterize the extent of the deletions at the INK4a–ARF loci, we also probed Southern blots with probes specific for INK4a exon1a and performed immunoblotting with antibodies specific for p16INK4a, an inhibitor of cyclin Ddependent kinases (Serrano et al. 1993).”
MethodGermline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Weinberger, P. M., Yu, Z., Haffty, B. G., Kowalski, D., Harigopal, M., Brandsma, J., Sasaki, C., Joe, J., Camp, R. L., Rimm, D. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.3335 · Cited by 796
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Pavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 744
“The p16INK4a inhibitor is a major tumor suppressor, being found mutated in about a third of all human cancers (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994). p21Cip1 stops the cell cycle on behalf of the p53 tumor suppressor, which is the most frequently mutated gene identi®ed in…”
BackgroundRegulation of p16 CDKN2 Expression and Its Implications for Cell Immortalization and Senescence
Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.859 · Cited by 733
“We and others have noted that in human cells transformed by DNA tumor viruses or lacking functional pRB, the D cyclins are not associated with their catalytic partners CDK4 or CDK6 (6, 60, 66).”
BackgroundInfluentialRegulation of NF-κB by Cyclin-Dependent Kinases Associated with the p300 Coactivator
Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., & Nabel, G. J. (1997) · Science · doi:10.1126/science.275.5299.523 · Cited by 722
Self-citationKato, J.-Y., Matsuoka, M., Polyak, K., Massague, J., & Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90257-7 · Cited by 720
Tumor surveillance via the ARF–p53 pathway
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 717
“The role of p16INK4a as an inhibitor of cyclin D-dependent kinases has been appreciated since its discovery (Serrano et al. 1993).”
BackgroundGuan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Distinct roles for E2F proteins in cell growth control and apoptosis
DeGregori, J., Leone, G., Miron, A., Jakoi, L., & Nevins, J. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7245 · Cited by 703
Requirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
Coats, S., Flanagan, W. M., Nourse, J., & Roberts, J. M. (1996) · Science · doi:10.1126/science.272.5263.877 · Cited by 679
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671
Strasser, A. (1994) · Cell · doi:10.1016/0092-8674(94)90201-1 · Cited by 666
Transcriptional Regulation of the p21(WAF1/CIP1)Gene
Gartel, A. L., & Tyner, A. L. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4319 · Cited by 664
A guide to assessing cellular senescence in vitro and in vivo
González‐Gualda, E., Baker, A. G., Fruk, L., & Muñoz‐Espín, D. (2021) · The FEBS Journal · doi:10.1111/febs.15570 · Cited by 645
Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence
Ohtani, N., Zebedee, Z., Huot, T. J. G., Stinson, J. A., Sugimoto, M., Ohashi, Y., Sharrocks, A. D., Peters, G., & Hara, E. (2001) · Nature · doi:10.1038/35059131 · Cited by 654
“jpg" NDATA ITEM> ]> The p16 INK4a cyclin-dependent kinase inhibito”
Metadata
- Authors
- Serrano, M., Hannon, G. J., & Beach, D.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Hannon, Gregory J.
- Venue
- Nature
- Published
- 1993-12
- Volume
- 366
- Issue
- 6456
- Pages
- 704-707
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066848701
- Cited by
- 3,650
- References
- 22
- Citations by year
- 2026: 36 · 2025: 46 · 2024: 52 · 2023: 66 · 2022: 67 · 2021: 78 · 2020: 64 · 2019: 63 · 2018: 56 · 2017: 70 · 2016: 69 · 2015: 75 · 2014: 52 · 2013: 98 · 2012: 88
- FWCI
- 78.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, CDK4, cyclin D, cyclin-dependent kinases, cell cycle regulation, G1 phase, kinase inhibition, retinoblastoma protein, p21, proliferating cell nuclear antigen, feedback regulation, cell proliferation
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carrier Proteins, Cell Cycle, Cloning, Molecular, DNA, Glutathione Transferase, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Oncogene Proteins, Retinoblastoma Protein, Cyclins, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.